Comparative Pharmacology
Head-to-head clinical analysis: OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN versus QDOLO.
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a mu-opioid receptor agonist, inhibiting neurotransmitter release and pain signal transmission. Acetaminophen inhibits cyclooxygenase (COX) enzymes, particularly in the central nervous system, reducing prostaglandin synthesis and pain perception.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Adults: 1-2 tablets (each containing 5 mg oxycodone/325 mg acetaminophen) orally every 4-6 hours as needed for pain; maximum 12 tablets per day (60 mg oxycodone/3900 mg acetaminophen).
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Oxycodone: 3.5-5.5 hours (immediate-release); Acetaminophen: 1.5-3 hours. Clinical context: renal/hepatic impairment prolongs half-life.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Oxycodone: primarily renal (10-20% unchanged, metabolites conjugated); Acetaminophen: renal (85-90%, primarily as glucuronide and sulfate conjugates, <5% unchanged).
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist